CN101878036A - 包含促胰岛素释放肽缀合物的治疗肥胖相关疾病的药物组合物 - Google Patents
包含促胰岛素释放肽缀合物的治疗肥胖相关疾病的药物组合物 Download PDFInfo
- Publication number
- CN101878036A CN101878036A CN2008801183534A CN200880118353A CN101878036A CN 101878036 A CN101878036 A CN 101878036A CN 2008801183534 A CN2008801183534 A CN 2008801183534A CN 200880118353 A CN200880118353 A CN 200880118353A CN 101878036 A CN101878036 A CN 101878036A
- Authority
- CN
- China
- Prior art keywords
- derivant
- group
- compositions
- insulinotropic peptide
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (24)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/947,697 US20090238838A1 (en) | 2003-11-13 | 2007-11-29 | Insulinotropic peptide conjugate using an immunoglobulin fc |
US11/947,697 | 2007-11-29 | ||
KR10-2008-0083194 | 2008-08-26 | ||
KR1020080083194A KR101135244B1 (ko) | 2007-11-29 | 2008-08-26 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
PCT/KR2008/007074 WO2009069983A2 (en) | 2007-11-29 | 2008-11-28 | A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101878036A true CN101878036A (zh) | 2010-11-03 |
CN101878036B CN101878036B (zh) | 2014-05-14 |
Family
ID=40988127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880118353.4A Active CN101878036B (zh) | 2007-11-29 | 2008-11-28 | 包含促胰岛素释放肽缀合物的治疗肥胖相关疾病的药物组合物 |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP2227243B1 (zh) |
JP (1) | JP5226080B2 (zh) |
KR (1) | KR101135244B1 (zh) |
CN (1) | CN101878036B (zh) |
AR (1) | AR069458A1 (zh) |
AU (1) | AU2008330315B2 (zh) |
BR (1) | BRPI0819864A2 (zh) |
CA (1) | CA2706627C (zh) |
DK (1) | DK2227243T3 (zh) |
ES (1) | ES2521497T3 (zh) |
HK (1) | HK1150029A1 (zh) |
HR (1) | HRP20140997T1 (zh) |
IL (1) | IL205667A (zh) |
MX (1) | MX2010005866A (zh) |
MY (1) | MY155454A (zh) |
NZ (1) | NZ585314A (zh) |
PL (1) | PL2227243T3 (zh) |
PT (1) | PT2227243E (zh) |
RU (1) | RU2446816C2 (zh) |
TW (1) | TWI403331B (zh) |
WO (1) | WO2009069983A2 (zh) |
ZA (1) | ZA201003796B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580087A (zh) * | 2012-03-08 | 2012-07-18 | 董萍 | 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法 |
CN104086655A (zh) * | 2013-04-02 | 2014-10-08 | 北京康华源科技发展有限公司 | 胰淀素样融合蛋白及其编码基因与应用 |
CN104684576A (zh) * | 2012-06-04 | 2015-06-03 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
CN104918954A (zh) * | 2013-01-03 | 2015-09-16 | 韩美药品株式会社 | N-末端电荷发生变化的胰岛素分泌肽衍生物 |
CN108125909A (zh) * | 2012-07-25 | 2018-06-08 | 韩美药品株式会社 | 长效促胰岛素分泌肽缀合物的液体制剂 |
CN104519871B (zh) * | 2012-07-25 | 2018-07-20 | 韩美药品株式会社 | 长效胰岛素缀合物的液体制剂 |
CN110075277A (zh) * | 2012-03-09 | 2019-08-02 | 韩美科学株式会社 | 用于预防或治疗非酒精性脂肪肝疾病的药学组合物 |
CN111818971A (zh) * | 2018-01-03 | 2020-10-23 | 梅德瑞斯糖尿病有限责任公司 | 用于治疗nash和其他紊乱的改进的肽药物 |
CN113181346A (zh) * | 2018-03-09 | 2021-07-30 | 上海仁会生物制药股份有限公司 | 用于治疗肥胖和体重管理的glp-1组合物 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
KR101502299B1 (ko) * | 2011-06-10 | 2015-03-11 | 한미사이언스 주식회사 | 신규한 옥신토모듈린 유도체 및 이를 포함하는 비만 치료용 조성물 |
MY164680A (en) * | 2011-06-17 | 2018-01-30 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
KR101350824B1 (ko) * | 2011-12-14 | 2014-01-13 | 서울대학교산학협력단 | 리파아제 특이적 지질-펩타이드 기질 라이브러리 및 이를 이용한 리파아제 저해제를 유효성분으로 함유하는 비만 및 지질대사 이상 관련 질환의 치료 및 예방용 약학적 조성물 |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
AU2013342321B2 (en) | 2012-11-06 | 2017-09-28 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
MX361083B (es) * | 2013-02-26 | 2018-11-27 | Hanmi Pharma Co Ltd | Conjugado de insulina específico de sitio. |
SG11201506937RA (en) * | 2013-03-05 | 2015-10-29 | Hanmi Pharm Ind Co Ltd | Improved preparation method for high-yield production of physiologically active polypeptide conjugate |
WO2014161835A1 (en) * | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
KR20180015131A (ko) | 2015-06-04 | 2018-02-12 | 안트리아바이오 인크. | 부위-특이적 단백질 콘쥬게이트의 제조를 위한 아민 페길화 방법 |
KR102193211B1 (ko) * | 2019-11-27 | 2020-12-18 | (주)디앤디파마텍 | 비오틴 모이어티가 결합된 폴리펩티드 및 이를 포함하는 경구 투여용 약학적 조성물 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
ATE316100T1 (de) | 1996-06-05 | 2006-02-15 | Roche Diagnostics Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
AU739020B2 (en) | 1997-01-07 | 2001-10-04 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
PT1019077E (pt) * | 1997-08-08 | 2008-02-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
PL393178A1 (pl) * | 2000-12-07 | 2011-02-14 | Eli Lilly And Company | Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulino-niezależną i kompozycja farmaceutyczna do leczenia pacjentów z otyłością |
IL141647A0 (en) | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
DK2256134T3 (en) * | 2003-11-13 | 2014-02-24 | Hanmi Science Co Ltd | IgG Fc fragment to a drug carrier and process for preparation thereof |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
ITPD20050253A1 (it) * | 2005-08-16 | 2007-02-17 | Sit La Precisa Spa | Dispositivo per il controllo multifunzionale dell'erogazione di un gas combustibile verso un apparecchio bruciatore |
JP2009513627A (ja) * | 2005-10-27 | 2009-04-02 | ペプトロン カンパニー リミテッド | 生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法 |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
-
2008
- 2008-08-26 KR KR1020080083194A patent/KR101135244B1/ko active IP Right Grant
- 2008-11-27 TW TW097145881A patent/TWI403331B/zh active
- 2008-11-28 AU AU2008330315A patent/AU2008330315B2/en active Active
- 2008-11-28 MX MX2010005866A patent/MX2010005866A/es active IP Right Grant
- 2008-11-28 RU RU2010126478/15A patent/RU2446816C2/ru active
- 2008-11-28 DK DK08855148.6T patent/DK2227243T3/da active
- 2008-11-28 AR ARP080105187A patent/AR069458A1/es not_active Application Discontinuation
- 2008-11-28 NZ NZ585314A patent/NZ585314A/xx active IP Right Revival
- 2008-11-28 WO PCT/KR2008/007074 patent/WO2009069983A2/en active Application Filing
- 2008-11-28 CA CA2706627A patent/CA2706627C/en active Active
- 2008-11-28 ES ES08855148.6T patent/ES2521497T3/es active Active
- 2008-11-28 PT PT88551486T patent/PT2227243E/pt unknown
- 2008-11-28 EP EP08855148.6A patent/EP2227243B1/en active Active
- 2008-11-28 MY MYPI2010002321A patent/MY155454A/en unknown
- 2008-11-28 JP JP2010535887A patent/JP5226080B2/ja active Active
- 2008-11-28 CN CN200880118353.4A patent/CN101878036B/zh active Active
- 2008-11-28 PL PL08855148T patent/PL2227243T3/pl unknown
- 2008-11-28 BR BRPI0819864A patent/BRPI0819864A2/pt not_active Application Discontinuation
-
2010
- 2010-05-10 IL IL205667A patent/IL205667A/en active IP Right Grant
- 2010-05-27 ZA ZA2010/03796A patent/ZA201003796B/en unknown
-
2011
- 2011-04-27 HK HK11104223.8A patent/HK1150029A1/zh unknown
-
2014
- 2014-10-17 HR HRP20140997AT patent/HRP20140997T1/hr unknown
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580087A (zh) * | 2012-03-08 | 2012-07-18 | 董萍 | 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法 |
CN102580087B (zh) * | 2012-03-08 | 2013-08-21 | 董萍 | 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法 |
CN110075277A (zh) * | 2012-03-09 | 2019-08-02 | 韩美科学株式会社 | 用于预防或治疗非酒精性脂肪肝疾病的药学组合物 |
CN104684576A (zh) * | 2012-06-04 | 2015-06-03 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
CN109096387A (zh) * | 2012-06-04 | 2018-12-28 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
CN109096387B (zh) * | 2012-06-04 | 2021-11-30 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
CN108125909A (zh) * | 2012-07-25 | 2018-06-08 | 韩美药品株式会社 | 长效促胰岛素分泌肽缀合物的液体制剂 |
CN104519871B (zh) * | 2012-07-25 | 2018-07-20 | 韩美药品株式会社 | 长效胰岛素缀合物的液体制剂 |
US10987424B2 (en) | 2012-07-25 | 2021-04-27 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting insulin conjugate |
CN104918954A (zh) * | 2013-01-03 | 2015-09-16 | 韩美药品株式会社 | N-末端电荷发生变化的胰岛素分泌肽衍生物 |
CN104086655B (zh) * | 2013-04-02 | 2019-02-15 | 常州博闻迪医药科技有限公司 | 胰淀素样融合蛋白及其编码基因与应用 |
CN104086655A (zh) * | 2013-04-02 | 2014-10-08 | 北京康华源科技发展有限公司 | 胰淀素样融合蛋白及其编码基因与应用 |
CN111818971A (zh) * | 2018-01-03 | 2020-10-23 | 梅德瑞斯糖尿病有限责任公司 | 用于治疗nash和其他紊乱的改进的肽药物 |
CN113181346A (zh) * | 2018-03-09 | 2021-07-30 | 上海仁会生物制药股份有限公司 | 用于治疗肥胖和体重管理的glp-1组合物 |
Also Published As
Publication number | Publication date |
---|---|
ES2521497T3 (es) | 2014-11-12 |
HRP20140997T1 (hr) | 2014-12-19 |
DK2227243T3 (da) | 2014-10-06 |
CN101878036B (zh) | 2014-05-14 |
RU2446816C2 (ru) | 2012-04-10 |
PT2227243E (pt) | 2014-10-22 |
EP2227243B1 (en) | 2014-08-13 |
EP2227243A2 (en) | 2010-09-15 |
WO2009069983A2 (en) | 2009-06-04 |
BRPI0819864A2 (pt) | 2017-05-23 |
JP2011505355A (ja) | 2011-02-24 |
NZ585314A (en) | 2012-10-26 |
PL2227243T3 (pl) | 2015-03-31 |
CA2706627C (en) | 2014-11-18 |
MY155454A (en) | 2015-10-15 |
KR101135244B1 (ko) | 2012-04-24 |
HK1150029A1 (zh) | 2011-10-28 |
MX2010005866A (es) | 2010-06-23 |
AR069458A1 (es) | 2010-01-20 |
IL205667A (en) | 2016-11-30 |
AU2008330315A1 (en) | 2009-06-04 |
CA2706627A1 (en) | 2009-06-04 |
ZA201003796B (en) | 2011-02-23 |
IL205667A0 (en) | 2010-11-30 |
WO2009069983A3 (en) | 2009-08-20 |
RU2010126478A (ru) | 2012-01-10 |
EP2227243A4 (en) | 2012-05-09 |
AU2008330315B2 (en) | 2012-06-21 |
TWI403331B (zh) | 2013-08-01 |
KR20090056796A (ko) | 2009-06-03 |
JP5226080B2 (ja) | 2013-07-03 |
TW200936154A (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101878036B (zh) | 包含促胰岛素释放肽缀合物的治疗肥胖相关疾病的药物组合物 | |
US8263084B2 (en) | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate | |
JP2022025114A (ja) | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 | |
KR101382593B1 (ko) | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 | |
CN107001439B (zh) | Gip激动剂化合物及方法 | |
CN103435700B (zh) | 使用免疫球蛋白片段的促胰岛素缀合物 | |
CN104918632B (zh) | 治疗糖尿病或糖胖病的包括胃泌酸调节素类似物的组合物 | |
TWI601744B (zh) | 包含調酸素與免疫球蛋白片段之複合物及其用途 | |
CN103596595A (zh) | 用于治疗糖尿病的包括长效胰岛素缀合物和长效促胰岛素肽缀合物的组合物 | |
RU2624129C2 (ru) | Способ получения комплекса физиологически активного полипептида | |
CN104093735A (zh) | 新的胰高血糖素类似物 | |
CN107106660A (zh) | 长效glp‑1/胰高血糖素受体双激动剂对于治疗非酒精性脂肪肝疾病的应用 | |
TW201333032A (zh) | 使用免疫球蛋白片段之位點專一性glp-2接合物 | |
WO2012136790A1 (en) | Compositions comprising fusion proteins or conjugates with an improved half -life |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HANMI HOLDINGS CO., LTD. Free format text: FORMER OWNER: HANMI PHARM. IND. CO., LTD. Effective date: 20110413 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: GYEONGGI-DO, SOUTH KOREA TO: SEOUL, SOUTH KOREA |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110413 Address after: Seoul, South Kerean Applicant after: Hanmi Pharm Ind Co.,Ltd. Address before: Gyeonggi Do, South Korea Applicant before: Hanmi Pharm. Ind. Co., Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1150029 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: HANMI SCIENCE CO., LTD. Free format text: FORMER OWNER: HANMI HOLDINGS CO., LTD. Effective date: 20120929 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120929 Address after: Gyeonggi Do, South Korea Applicant after: Hanmi Holdings Co., Ltd. Address before: Seoul, South Kerean Applicant before: Hanmi Pharm Ind Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1150029 Country of ref document: HK |